Andrx Announces Filing of NDA by Takeda for ACTOS and Extended-Release Metformin Combination Product.
Business Wire › April 04, 2006
Linked as:
Extract
Andrx Announces Filing of NDA by Takeda for ACTOS and Extended-Release Metformin Combination Product.
FORT LAUDERDALE, Fla. -- Andrx Corporation (Nasdaq:ADRX) announced today that Takeda Global Research & Development Center Inc. filed a New Drug Application (NDA) for a combination product consisting of Takeda's ACTOS(R) (pioglitazone HCl) and Andrx's extended-release metformin to the U.S. Food and Drug Administration ...
See the full content of this document
Sponsored links
